Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark†
Article first published online: 25 JUL 2008
Copyright © 2008 Wiley-Liss, Inc.
International Journal of Cancer
Volume 123, Issue 8, pages 1864–1870, 15 October 2008
How to Cite
Kjær, S. K., Breugelmans, G., Munk, C., Junge, J., Watson, M. and Iftner, T. (2008), Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int. J. Cancer, 123: 1864–1870. doi: 10.1002/ijc.23712
Conflict of Interest: SKK is a member of the Scientific Steering Committee for Merck. She has received travel and research grants from Merck and Sanofi Pasteur MSD. CM has received support for travel and conference participation from Merck. GB and MW formerly worked for SP MSD that commercializes Gardasil in Europe.
- Issue published online: 13 AUG 2008
- Article first published online: 25 JUL 2008
- Manuscript Accepted: 22 APR 2008
- Manuscript Received: 30 OCT 2007
- Sanofi Pasteur MSD (Lyon, France)
- Danish Cancer Society
- cervical intraepithelial neoplasia;
- cervical cancer
Knowledge about the prevalence of human papillomavirus (HPV) on a population level is important. We conducted a large population-based study in Denmark to determine the overall and age-specific HPV prevalence, and HPV type distribution in women. Liquid-based cytology samples (SurePath®) were collected consecutively. HPV testing was performed with Hybrid Capture 2 (HC2; Digene) (high-risk and low-risk probes), and LiPA (Innogenetics) was used for genotyping. We analyzed samples from 11,617 women; 94.0% had normal cytology, 4.3% atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion and 1.6% had high-grade squamous intraepithelial lesion (HSIL). The HPV prevalence was 26.4% with a peak in women 20–24 years (50.2%) and then decreased without a second peak in older women. Among the youngest women (15–19 years), 14% had HPV 16/18 and 16% had HPV 6/11. Prevalence of high-risk HPV types increased from 19.2% in women with normal cytology to 100% in women with cervical intraepithelial neoplasia grade 3 (CIN3)/cervical cancer. HPV 16 was the most prevalent type (6.0% of all women), and was also the most prevalent in women with HSIL (35.1%) and CIN3 (53.2%). Other common HPV types in women with CIN3 included HPV 52, 51, 31, 33 and 18. HPV 16/18 alone was present in 23% of CIN3 lesions and 67% of cervical cancers, and HPV 16/18 together with other high-risk HPV types was present in 41% of CIN3 lesions. This suggests that an efficacious HPV 16/18 vaccine will have a substantial preventive potential in the general female population. © 2008 Wiley-Liss, Inc.